arGEN-X SE ADR (ARGX): Price and Financial Metrics

arGEN-X SE ADR (ARGX): $360.23

1.82 (+0.51%)

POWR Rating

Component Grades








Add ARGX to Watchlist
Sign Up

Industry: Biotech




#153 of 362

in industry

ARGX Price/Volume Stats

Current price $360.23 52-week high $550.76
Prev. close $358.41 52-week low $327.73
Day low $357.55 Volume 331,500
Day high $362.54 Avg. volume 319,695
50-day MA $387.64 Dividend yield N/A
200-day MA $443.75 Market Cap 21.36B

ARGX Stock Price Chart Interactive Chart >

arGEN-X SE ADR (ARGX) Company Bio

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021. (Source:Wiki)

ARGX Latest News Stream

Event/Time News Detail
Loading, please wait...

ARGX Latest Social Stream

Loading social stream, please wait...

View Full ARGX Social Stream

Latest ARGX News From Around the Web

Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

UPDATE 2-European shares end slightly higher ahead of Christmas holiday

European stocks closed with a whimper on Friday, as softer-than-expected U.S. inflation data offset losses in sportwear makers and China-exposed stocks ahead of the Christmas holiday weekend. The pan-European STOXX 600 index edged up 0.1% and notched its sixth week of gains in a row - a winning streak that was last seen in December 2022. European markets will be shut on Monday for Christmas.

Yahoo | December 22, 2023

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off

Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.

Yahoo | December 21, 2023

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Yahoo | December 21, 2023

Why Is Argenx (ARGX) Stock Down 25% Today?

Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.

Josh Enomoto on InvestorPlace | December 20, 2023

Stock Market Does Sharp About-Face; Dow Breaks Win Streak

Stock market indexes unexpectedly reversed course in afternoon trading Wednesday, sending the major indexes lower by more than 1%. The Dow Jones Industrial Average couldn't add to its nine-day win streak after reaching all-time highs.

Yahoo | December 20, 2023

Read More 'ARGX' Stories Here

ARGX Price Returns

1-mo 0.92%
3-mo -1.82%
6-mo -24.17%
1-year -5.21%
3-year 29.42%
5-year 204.51%
YTD -5.31%
2023 0.42%
2022 8.18%
2021 19.08%
2020 83.21%
2019 67.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!